Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Shares Issued: 2022-2025

Historic Shares Issued for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $2.5 million.

  • Stoke Therapeutics' Shares Issued rose 1689.93% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 299.05%. This contributed to the annual value of $1.7 million for FY2024, which is 210.27% up from last year.
  • Stoke Therapeutics' Shares Issued amounted to $2.5 million in Q3 2025, which was up 349.10% from $554,000 recorded in Q2 2025.
  • Stoke Therapeutics' Shares Issued's 5-year high stood at $2.5 million during Q3 2025, with a 5-year trough of $1,000 in Q4 2023.
  • Over the past 3 years, Stoke Therapeutics' median Shares Issued value was $348,000 (recorded in 2023), while the average stood at $574,818.
  • Its Shares Issued has fluctuated over the past 5 years, first crashed by 80.80% in 2023, then spiked by 56,600.00% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Shares Issued (Quarterly) stood at $151,000 in 2022, then surged by 130.46% to $1,000 in 2023, then skyrocketed by 56,600.00% to $567,000 in 2024, then soared by 1,689.93% to $2.5 million in 2025.
  • Its Shares Issued stands at $2.5 million for Q3 2025, versus $554,000 for Q2 2025 and $1.0 million for Q1 2025.